At a glance
- Originator Merck & Co
- Class Antibacterials; Depsipeptides; Peptide antibiotics
- Mechanism of Action Complement C5a inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Jul 1995 Preclinical development for Bacterial infections in USA (Unknown route)